French cancer alliance gets backing
Paris – France’s BioAlliance Pharma SA has pocketed EUR6.4m in funding from the French state innovation agency OSEO under its Cancer Anti-invasive Program (CAP). The company will now lead a consortium of four biotech companies and three academic institutions working on the commercialisation of two new cancer drugs. The first is AMEPTM, a biotherapy indicated in invasive melanoma, while the second is the first-in-class anti-cancer drug to target invasive cancers and make tumour cells revert to a normal phenotype. In parallel, the consortium will also be developing novel animal models of invasive cancers with Xentech, highly predictive genotoxicity tests with Oroxcell, and immunotoxicology tools with CIT, while Novasep will be developing an R&D-phase pilot facility for generating highly potent active ingredients (HPAIs). In collaboration with BioAlliance Pharma, the academic centres of excellence have been given the task of identifying new markers for monitoring tumour invasion.